There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579
Recruiting
The purpose of this trial is to estimate the recommended dose (RD) of \[177Lu\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor-2 (HER2) negative (HER2-) and gastrin releasing peptide receptor (GRPR) positive (GRPR+) advanced breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy or who have progressed on endocrine therapy in combination with a CDK4/6 inhibitor for adva... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/19/2025
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +19 locations
Conditions: Breast Cancer
Register for Updates
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
NCT06557148
Recruiting
The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET/CT (positron emission tomography/computed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET/CT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET/CT scans and FDG PET/CT scans.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Lobular Breast Carcinoma, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Lobular Breast Carcinoma, Metastatic Breast Carcinoma
Register for Updates
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT06246968
Recruiting
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma
Register for Updates
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT06144164
Recruiting
The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/16/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm, Breast Cancer, Breast Carcinoma, Female Breast Cancer
Register for Updates
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
NCT05590949
Recruiting
The purpose of this study to gather information about changes in the bones after stopping treatment with aromatase inhibitor/AI and denosumab. The study team will collect information from 5 standard clinic visits over the course of 24 months. The information will include information about participant health assessments, blood test results, and imaging results. After 24 months, participation in this study will be complete.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer
Register for Updates
Preoperative Irradiation for Stage I Breast Cancer
NCT05464667
Recruiting
The novel use of preoperative RT will have broad implications for breast cancer patients, most of whom present with early-stage disease. In the era of reduced chemotherapy delivery, preoperative RT will allow oncologists to assess radiologic and biologic tumor response and correlate it to outcomes. Underutilization of RT negatively affects mortality. This trial aims to further evaluate pre-operative radiation therapy in patients with early stage, biologically favorable breast cancer, with improv... Read More
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
05/15/2025
Locations: UPMC Magee Womens Hospital - Radiation Oncology, Pittsburgh, Pennsylvania
Conditions: Breast Cancer
Register for Updates
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT05534438
Recruiting
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +7 locations
Conditions: Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Register for Updates
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT05123482
Recruiting
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Research Site, Duarte, California +65 locations
Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Carcinoma, Squamous Non-Small Cell Lung Cancer
Register for Updates
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264
Recruiting
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor rece... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Hoag Memorial Presbyterian, Newport Beach, California +32 locations
Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Register for Updates
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692
Recruiting
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Arizona Oncology Associates, Tucson, Arizona +11 locations
Conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT05856773
Recruiting
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall and regional lymph nodes.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
05/14/2025
Locations: California Protons Cancer Therapy Center, San Diego, California +4 locations
Conditions: Breast Cancer
Register for Updates
A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer
NCT06813053
Recruiting
This is a study to assess the feasibility and acceptability of a novel decision aid (DA) in a newly diagnosed, early-stage breast cancer population. Insights gained from patient feedback and the implementation process will be used to improve the information delivered in the decision aid itself and to plan for a larger scale trial to compare the decision aid to standard of care.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
05/14/2025
Locations: Universtiy of Colorado Hospital, Aurora, Colorado +2 locations
Conditions: Breast Cancer
Register for Updates